Description
Trametinib is used alone or in combination with dabrafenib (Tafinlar) to treat certain types of melanoma (a type of skin cancer). It is also used in combination with dabrafenib to prevent the return of a certain type of melanoma after surgery.
In May 2013, trametinib was approved as a single-agent by the US Food and Drug Administration for the treatment of people with V600E mutated metastatic melanoma. It was approved for medical use in the European Union in June 2014.